Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
Public ClinicalTrials.gov record NCT02581865. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Adult Subjects With Tourette Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment. This study will enroll approximately 90 male and female subjects clinically diagnosed with Tourette Syndrome.
Study identification
- NCT ID
- NCT02581865
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2015
- Primary completion
- Nov 30, 2016
- Completion
- Nov 30, 2016
- Last update posted
- May 6, 2020
2015 – 2016
United States locations
- U.S. sites
- 30
- U.S. states
- 16
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Long Beach | California | — | — |
| Not listed | National City | California | — | — |
| Not listed | San Bernardino | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Upland | California | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Natick | Massachusetts | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Nashua | New Hampshire | — | — |
| Not listed | Summit | New Jersey | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Manhasset | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Staten Island | New York | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Norristown | Pennsylvania | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | Orem | Utah | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Kirkland | Washington | — | — |
| Not listed | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02581865, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2020 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02581865 live on ClinicalTrials.gov.